Accessibility Menu
Noveris Health Sciences logo

Noveris Health Sciences(OTC) MYCOF

Market Cap$42.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-100%
1 Year+441%
1 Month-34%
$0.73
+0.00%
+0.00Today
Noveris Health Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.732026-08-14
Noveris Health Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.732026-08-07
1 month-33.64%USD 1.102026-07-13
3 month-32.41%USD 1.082026-05-15
Year to date+234.52%USD 0.222025-12-31
1 year+440.74%USD 0.142025-08-14
3 year-85.64%USD 5.092023-08-14
5 year-99.95%USD 1,480.692021-08-13
Since inception-100%USD 19,237.482015-05-08

Noveris Health Sciences Financials at a Glance

Market Cap

$42.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

CA$1.60M

EPS (TTM)

$1.80

P/E Ratio

0.41

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.73

Volume

4

Open

$0.73

Previous Close

$0.73

Daily Range

$0.73 - $0.73

52-Week Range

$0.01 - $2.04

Estimated Earnings Date

Aug 17, 2026

MYCOF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Noveris Health Sciences

Noveris Health Sciences Inc. is a biotechnology firm focused on the research, development, and clinical evaluation of psilocybin-based products. Established in 2013 and headquartered in Vancouver, Canada, the company aims to innovate within the pharmaceutical industry.

Products and Services
  • Development of psilocybin-based therapeutic products
  • Clinical trials to evaluate product efficacy and safety
  • Research initiatives in mental health treatment solutions
Growth Outlook
  • Significant market potential in the mental health sector
  • Increasing acceptance of psychedelic therapies in mainstream medicine
  • Strategic partnerships to enhance research capabilities and market reach
Financial Highlights
  • Recent quarterly net income of -$1,620,678, reflecting ongoing investment in R&D
  • Trailing twelve months (TTM) revenue of $0, indicating early-stage development
  • Cash and cash equivalents of $2,032,921, providing operational runway
Noveris Health Sciences Inc. operates in a rapidly evolving sector, with a focus on psilocybin-based therapies that have garnered increasing attention for their potential in treating mental health disorders. The company's commitment to research and development positions it well to capitalize on emerging trends in the pharmaceutical landscape. Despite current financial challenges, including a recent quarterly net loss, the available cash reserves suggest a capacity to sustain operations while pursuing innovative solutions. The growth outlook remains promising, driven by a favorable regulatory environment and shifting perceptions towards psychedelic treatments.
AI Generated • Jul 24, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

Vancouver, BC V6E 3C9, CA

MYCOF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

2.04%

Return on Capital

N/A

Return on Assets

-133249.15%

Earnings Yield

2.44%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$42.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

58.55M

Volume

4

Avg. Volume

408.365

Financials (TTM)

Gross Profit

CA$0.00

Operating Income

-CA$497.06K

EBITDA

CA$2.98M

Operating Cash Flow

-CA$284.65K

Capital Expenditure

CA$0.00

Free Cash Flow

-CA$284.66K

Cash & ST Invst.

CA$2.03M

Total Debt

CA$424.27K

Noveris Health Sciences Performance Analysis

Noveris Health Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Noveris Health Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3095.8%
Q32025-09-3029900.0%
Q42025-12-314195.3%
Q12026-03-31-103.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

CA$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$42.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$14.25M

N/A

Employees

3

N/A

Net Income

-CA$1.62M

-442.3%

EBITDA

-CA$321.26K

-103.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CA$2.03M

+20576.6%

Total Debt

CA$424.27K

-94.0%

Accounts Receivable

CA$0.00

N/A

Inventory

CA$0.00

N/A

Long Term Debt

CA$0.00

N/A

Short Term Debt

CA$424.27K

-94.0%

Return on Assets

-1332.49%

N/A

Return on Invested Capital

4.01%

N/A

Free Cash Flow

-CA$284.52K

-3092.8%

Operating Cash Flow

-CA$284.52K

-3092.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TELIFTelescope Innovations Corp.
$0.31+0.65%
PTKFYPT Kalbe Farma Tbk
$8.78+0.00%
LUFFFHerbal Dispatch Inc.
$0.02+0.41%
BTCYBiotricity, Inc.
$0.12-1.69%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About MYCOF

What is the current price of Noveris Health Sciences?

Noveris Health Sciences is trading at $0.73 per share.

What is the 52-week range for Noveris Health Sciences?

Over the past 52 weeks, Noveris Health Sciences has traded between $0.01 and $2.04.

How much debt does Noveris Health Sciences have?

Noveris Health Sciences total debt is unavailable.

How much cash does Noveris Health Sciences have on hand?

Noveris Health Sciences does not have cash on hand data available.

What is Noveris Health Sciences’s dividend yield?

Noveris Health Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services